Focused On-demand Library for tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96G46

UPID:

DUS3L_HUMAN

Alternative names:

mRNA-dihydrouridine synthase DUS3L; tRNA-dihydrouridine synthase 3-like

Alternative UPACC:

Q96G46; Q96HM5; Q9BSU4; Q9H877; Q9NPR1

Background:

The tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like, also known as mRNA-dihydrouridine synthase DUS3L and tRNA-dihydrouridine synthase 3-like, plays a crucial role in RNA modification. It catalyzes the synthesis of dihydrouridine in various RNAs, including tRNAs, mRNAs, and lncRNAs, primarily modifying the uridine at position 47 in the D-loop of most cytoplasmic tRNAs. This modification process is vital for the proper functioning of these RNAs.

Therapeutic significance:

Understanding the role of tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like could open doors to potential therapeutic strategies. Its involvement in the modification of RNAs highlights its importance in cellular processes and its potential as a target for drug discovery.